Venkatreddy Alugubelli, MD
Geriatric Medicine · Beverly Hills, FLNPI 1417059056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $675 and has fallen 62.1% since, to $256 in 2025.
Across 128 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$335
- AstraZeneca$275
- Amarin Pharma, Inc.$212
- GSK$198
- Esperion Therapeutics, Inc.$195
- Amgen$175
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,52094%
- Education$1706%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 11 | $335 |
| AstraZeneca | 15 | $275 |
| Amarin Pharma, Inc. | 10 | $212 |
| GSK | 10 | $198 |
| Esperion Therapeutics, Inc. | 6 | $195 |
| Amgen | 10 | $175 |
| Novo Nordisk | 12 | $174 |
| Boehringer Ingelheim | 8 | $170 |
| Boston Scientific | 2 | $165 |
| Novartis | 7 | $138 |
| Bayer | 6 | $112 |
| AbbVie(2 entities) | 5 | $108 |
| Lilly USA, LLC | 7 | $101 |
| Biogen | 4 | $76 |
| Johnson & Johnson | 3 | $48 |
| Eisai Inc. | 2 | $44 |
| Abbott | 2 | $40 |
| Pfizer | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$125
- NEXLIZET$120
- NEXLETOL$120
How this compares
$2,690 in reported general payments places this provider in the 85th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 170 | $231,038 |
| OzempicSemaglutide | 117 | $175,445 |
| EliquisApixaban | 99 | $131,137 |
| FarxigaDapagliflozin Propanediol | 85 | $114,314 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $109,565 |
| TrulicityDulaglutide | 54 | $97,192 |
| JanuviaSitagliptin Phosphate | 47 | $70,761 |
| XareltoRivaroxaban | 53 | $49,596 |
| MounjaroTirzepatide | 24 | $37,133 |
| RybelsusSemaglutide | 18 | $36,491 |
| MyrbetriqMirabegron | 31 | $31,404 |
| EntrestoSacubitril/Valsartan | 16 | $30,700 |
| NexletolBempedoic Acid | 27 | $27,738 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $23,817 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $17,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $170 | $231,038170 claims |
| Novo NordiskOzempic, Rybelsus | $174 | $211,936135 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $198 | $146,301120 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $275 | $139,422134 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $101 | $134,32578 claims |
| PfizerEliquis | $34 | $131,13799 claims |
| MerckJanuvia | $14 | $70,76147 claims |
| Johnson & JohnsonXarelto | $48 | $49,59653 claims |
| Astellas Pharma US IncMyrbetriq | $335 | $31,40431 claims |
| NovartisEntresto | $138 | $30,70016 claims |
| Esperion Therapeutics, Inc.Nexletol | $195 | $27,73827 claims |
| AbbVieLinzess, Synthroid | $108 | $17,395105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Beverly Hills
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.